Pavani Chalasani, MD
Enriched profileDivision Director Hematology Oncology, George Washington University [ORCID self-attested] · George Washington University
Pavani Chalasani is Division Director Hematology Oncology, George Washington University [ORCID self-attested] at George Washington University. OpenAlex indexes 271 publications with 2,234 citations (h-index 23); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 23 Oct 2026
Pavani Chalasani, M.D, is Division Director Hematology Oncology, George Washington University [ORCID self-attested]. The public record shows 271 publications with 2,234 citations (h-index 23), centered on Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 10 companies.
- Most recent indexed publication: 2026 · The oncologist
- Top research focus: Breast Cancer Treatment Studies
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 44.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
- CtDNA Based MRD Testing for NAC Monitoring in TNBC
Sponsor: Personalis Inc.
Industry payments
Updated 23 Oct 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Stemline Therapeutics Inc.Program year20252 payments
- PFIZER INC.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
89.5%Aromatase Inhibitor72.6%Anastrozole87%Letrozole13%Part D<11 patientsKinase inhibitor11.3%Verzenio100%Part D<11 patients+ 1 more class in this area
Sensory organs
5.6%Corticosteroid5.6%Dexamethasone100%Part D<11 patientsMetabolism & gastrointestinal
4.8%Serotonin-3 Receptor Antagonist4.8%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 23 Oct 2026
55 congress contributions (2010–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 2854: Antibiotics blunt the innate immune mechanisms underlying HER2+ breast cancer therapy efficacy
AACR Annual Meeting
AACR2026Co-author - Abstract 2880: Antibiotic driven microbiota disruption impairs HER2 targeted therapy efficacy
AACR Annual Meeting
AACR2026Co-author - Abstract 3680: Attitudes, beliefs, and perceptions of clinicians on AI-assisted digital health interventions for oncofertility education
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Evaluation of dronabinol to decrease opioid use for cancer-induced bone pain.
The oncologist
Clinical Trial2026 - Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.
Clinical cancer research
Article2023 - Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study.
Molecular cancer therapeutics
Clinical Trial2023 - Transcranial Magnetic Stimulation for the Treatment of Chemo Brain.
Sensors (Basel, Switzerland)
Case Report2023 - Social Determinants of Health and Symptom Burden During Cancer Treatment.
Nursing research
Article2023
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumorsArticle233 citations2021
- 04Clinical Translation of Tumor Acidosis Measurements with AcidoCEST MRIArticle103 citations2016
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/pavani-chalasani-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancercenter.gwu.edu ↗
Editorial & leadership roles
journal and society appointments- Advisory committee member
Breast Cancer Project, Association of Cancer Care Centers (ACCC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →accc-cancer.org ↗ - Chair
Scientific Review Committee, University of Arizona Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthsciences.arizona.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthsciences.arizona.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthsciences.arizona.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Cynthia Tracy, MD
George Washington University
Ted Rothstein, MD
George Washington University
Paul Kimmel, MD
George Washington University
Joel W. Greer
George Washington University
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope